Meissa Vaccines provides update on vaccine candidates for COVID-19 and RSV

COVID-19 vaccine candidate designed as a single, intranasal dose; preliminary clinical data show RSV vaccine is heavily attenuated and induces a RSV-specific mucosal IgA response

DDNews Staff
Register for free to listen to this article
Listen with Speechify
0:00
5:00
SOUTH SAN FRANCISCO, Calif.—Meissa Vaccines, a biotechnology company developing vaccines to prevent viral respiratory infections, announced in late June that it has initiated preclinical studies and manufacturing and completed a pre-IND meeting with the U.S. Food and Drug Administration (FDA) for the development of MV-014-210, a live attenuated vaccine (LAV) to induce immunity and protect against SARS-CoV-2, the novel coronavirus that causes COVID-19.
 
Meissa also announced interim results from the first-in-human study of MV-012-968, the company’s LAV candidate for respiratory syncytial virus (RSV), showing that the candidate generates an immune response in healthy adults. These initial clinical data support the further development of MV-012-968 for RSV and the application of Meissa’s technology to a COVID-19 vaccine candidate, according to the company
 
Meissa’s COVID-19 vaccine candidate, MV-014-210, was developed on the company’s codon deoptimized RSV vaccine platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines. The company’s platform technology can potentially solve challenging obstacles in modern vaccinology such as suboptimal immune responses, vaccine stability and manufacturing.
 
The Meissa COVID-19 vaccine candidate MV-014-210 was derived by modifying the RSV MV-012-968 LAV, replacing the RSV glycoproteins with a functioning fusogenic SARS-CoV-2 Spike protein. MV-014-210 is designed to be administered as a single needle-free, adjuvant-free dose to protect against COVID-19. Meissa’s COVID-19 vaccine candidate offers significant potential advantages for global deployment including easy intranasal administration, a single dose to induce systemic and mucosal immunity and a simple, economical and scalable manufacturing process capable of supplying global demands. Clinical trials are expected to begin in early 2021.
 
“The COVID-19 vaccine pipeline is dominated by non-replicating vaccines, while live attenuated vaccines are known to induce long-lasting immunity after a single adjuvant-free intranasal low dose, presenting an economical and effective solution to this global pandemic,” said Dr. Martin Moore, co-founder and CEO of Meissa. “A single dose of MV-014-210 may be sufficient to generate immunity against SARS-CoV-2.”
 
In animal models evaluated previously, Meissa’s RSV LAV candidate MV-012-968 induced a strong mucosal IgA response and a serum-neutralizing antibody response against RSV. MV-012-968 has been safe and well-tolerated among healthy RSV sero-low adults assessed through day 56 in an ongoing randomized, open-label, dose-ranging Phase 1a trial (ClinicalTrials.gov Identifier NCT04227210). A 106 PFU dose of MV-012-968 resulted in no detectable shed vaccine virus nasally, indicating heavy attenuation, and yet induced RSV-specific mucosal IgA in the majority of vaccine recipients.
 
Concluded. Moore: “The promising clinical data from our RSV vaccine candidate showing that it generated an immune response and has been safe and well-tolerated in healthy individuals further supports the application of Meissa’s technology to a COVID-19 vaccine candidate as well as continued development of MV-012-968 for RSV.”

DDNews Staff

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2023 magazine issue front cover

Latest Issue  

• Volume 19 • Issue 11 • November 2023

November 2023

November 2023 Issue